Ultragenyx Pharmaceutical
RARE
16.48
-0.74
-4.30%
Ultragenyx Pharmaceutical
US · RARE
#3012 by market cap
Listed 1970
16.48
-0.74
-4.30%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:31
Recent news
-
H.C. Wainwright Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Maintains Target Price $25Market Newswire · 2026/11/7
-
Company notice
China Rare Earth Nonferrous: Notice of China Rare Earth Nonferrous Metals Co., Ltd. on Convening the Third Extraordinary Shareholders' Meeting of 2026SZSI · 2026/11/13
-
Company notice
Renet Japan Group: Selected for Tokyo's "Rare Resource Emergency Collection Project." In collaboration with the Tokyo Metropolitan Government, we will further accelerate the collection of used personal computers.JPX · 2026/10/22
-
Company notice
Fuji Die: The "Susteroi STN30," which reduces rare-metal usage by 90%, has been awarded the "Technical Achievement Award" at the Japan Machine Tool Industry Association Awards.JPX · 2026/10/26
-
Rating change
Lynas Rare Earths Price Target Cut 2.7% to A$17.50/Share by JefferiesDow Jones · 2026/10/30
-
Rating change
BMO Capital Initiates LYNAS RARE EARTHS LTD(LYSCF.US) With Buy Rating, Announces Target Price $11.95Market Newswire · 2026/11/2
-
Company notice
Fuji Die: The development of [Susteroi STN30], which reduces rare metal usage by 90%, has been awarded the "Minister of Economy, Trade and Industry Award" at the 42nd Basic Materials Industry Technology Awards.JPX · 2026/11/10
-
BofA Securities Maintains Ultragenyx Pharmaceutical(RARE.US) With Hold Rating, Maintains Target Price $20Market Newswire · 2026/11/4
-
A Quick Look at Today's Ratings for Ultragenyx Pharmaceutical(RARE.US), With a Forecast Between $22 to $36Market Newswire · 2026/11/6
-
Rating change
TD Cowen Maintains LYNAS RARE EARTHS LTD(LYSCF.US) With Hold Rating, Cuts Target Price to $9.79Market Newswire · 2026/11/3
-
Citi Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Maintains Target Price $22Market Newswire · 2026/11/7
-
Rating change
Lynas Rare Earths Price Target Cut 11% to A$20.50/Share by Canaccord GenuityDow Jones · 2026/10/30
-
Rating change
Cantor Fitzgerald Maintains USA Rare Earth(USAR.US) With Buy Rating, Cuts Target Price to $30Market Newswire · 2026/11/10
-
Company notice
Rare Element Resources Ltd. | 10-Q: Quarterly reportSEC · 2026/11/5
-
Rating change
Ord Minnett Downgrades LYNAS RARE EARTHS LTD(LYSCF.US) to Hold Rating, Cuts Target Price to $9.49Market Newswire · 2026/10/30
-
Rating change
Canaccord Genuity Adjusts Lynas Rare Earths' Price Target to AU$20.50MT Newswires · 2026/10/30
-
Rating change
Northland Securities Maintains USA Rare Earth(USAR.US) With Buy Rating, Cuts Target Price to $20Market Newswire · 2026/11/14
-
A Quick Look at Today's Ratings for Ultragenyx Pharmaceutical(RARE.US), With a Forecast Between $17 to $36Market Newswire · 2026/11/5
-
Rating change
Roth MKM Maintains USA Rare Earth(USAR.US) With Buy Rating, Cuts Target Price to $20Market Newswire · 2026/11/11
-
Rating change
UBS Initiates LYNAS RARE EARTHS LTD(LYSCF.US) With Buy Rating, Announces Target Price $14.78Market Newswire · 2026/10/30
-
UBS Downgrades Ultragenyx Pharmaceutical(RARE.US) to Hold Rating, Cuts Target Price to $16Market Newswire · 2026/10/15
-
BofA Securities Maintains Ultragenyx Pharmaceutical(RARE.US) With Hold Rating, Maintains Target Price $20Market Newswire · 2026/10/9
-
H.C. Wainwright Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Maintains Target Price $25Market Newswire · 2026/10/15
-
Company notice
Jiangxi Jiangtung Equipment: Sponsorship Report by CITIC Securities Co., Ltd. on the Issuance of Shares by Jiangxi Jiangtung Rare and Precious Equipment Co., Ltd. to Specific InvestorsSZSI · 2026/10/10
-
Piper Sandler Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Cuts Target Price to $36Market Newswire · 2026/10/21
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-11-20 19:31:44 · For reference only, not investment advice and not tailored to your situation.
Ultragenyx Pharmaceutical discussion 0 comments